TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY

被引：0
|
作者：
Bell, J. [1 ]
Galaznik, A. [1 ]
Farrelly, E. [2 ]
Blazer, M. [2 ]
Shih, H-C. [2 ]
Raju, A. [2 ]
Ogbonnaya, A. [2 ]
Eaddy, M. [2 ]
Fram, R. [1 ]
Faller, D. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Xcenda, Palm Harbor, FL USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1196
引用
收藏
页码：491 / 492
页数：2
相关论文
共 50 条
  • [21] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Zimmerman, Cassie
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Kantarjian, Hagop
    Zell, Katrina
    Wang, Quiqing
    Gore, Steven D.
    Nazha, Aziz
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [22] Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Zeidan, Amer M.
    Philipp, Jan
    Bewersdorf, Philipp
    Hasle, Vanessa
    Thompson, Ethan G.
    de Menezes, Daniel Lopes
    Rose, Shelonitda
    Boss, Isaac
    Fox, Brian
    BLOOD, 2021, 138
  • [23] Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Mufti, Ghulam J.
    Silverman, Lewis R.
    Best, Steven
    Fructman, Steve
    Azarnia, Nozar
    Petrone, Michael E.
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [24] Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?
    Deveaux, Michelle
    Stahl, Maximilian
    Giri, Smith
    Wang, Rong
    Podoltsev, Nikolai A.
    Ma, Xiaomei
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [25] Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients With Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Johnson, Lisa
    Zhang, Yajia
    Su-Feher, Linda
    Lee, Yeonju
    Sallman, David A.
    Asch, Adam S.
    Al Malki, Monzr M.
    Kim, Hyunjae Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S368 - S369
  • [26] ECONOMIC IMPACT OF TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML) AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HIGHER-RISK MDS) IN THE UNITED STATES: RETROSPECTIVE MATCHED COHORT STUDY
    Kota, V.
    Ogbonnaya, A.
    Farrelly, E.
    Schroader, B. Kanz
    Kristo, F.
    Raju, A.
    Dalal, M.
    LEUKEMIA RESEARCH, 2021, 108 : S26 - S27
  • [27] CHARACTERIZATION OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: ANALYSIS OF UNITED STATES COMMERCIAL CLAIMS DATABASE
    Mehra, M.
    Potluri, R.
    He, J.
    Fleischmann, J.
    Bussolari, J.
    Desai, A.
    HAEMATOLOGICA, 2016, 101 : 500 - 500
  • [28] Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
    Bewersdorf, Jan Philipp
    Wei, Wei
    Jaiani, Anna
    Patel, Prital
    Mehta, Rajni
    Neparidze, Natalia
    Shallis, Rory M.
    Podoltsev, Nikolai
    Brunner, Andrew M.
    Zeidan, Amer M.
    BLOOD, 2021, 138 : 3701 - +
  • [29] Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA)
    Komrokji, Rami S.
    Donoso, Leyla Hernandez
    Hodzic, Sejla
    Owusu, Henry F.
    Nolan, Kevin
    Nourry, Claire
    Diez-Campelo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
    Bewersdorf, Philipp
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Ramaswamy, Rahul
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Gurnari, Carmelo
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
12345